The Association of Plasma Amyloid-β and Cognitive Decline in Cognitively Unimpaired Population

References

• Jia L, Quan M, Fu Y, et al. Dementia in China: epidemiology, clinical management, and research advances. Lancet Neurol. 2020;19(1):81–92. doi:10.1016/S1474-4422(19)30290-X
   PubMed Web of Science ®Google Scholar
• Busche MA, Hyman BT. Synergy between amyloid-beta and tau in Alzheimer’s disease. Nat Neurosci. 2020;23(10):1183–1193. doi:10.1038/s41593-020-0687-6
   PubMed Web of Science ®Google Scholar
• Frisoni GB, Altomare D, Thal DR, et al. The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. Nat Rev Neurosci. 2022;23(1):53–66. doi:10.1038/s41583-021-00533-w
   PubMed Web of Science ®Google Scholar
• Kametani F, Hasegawa M. Reconsideration of amyloid hypothesis and tau hypothesis in Alzheimer’s disease. Front Neurosci. 2018;12:25. doi:10.3389/fnins.2018.00025
   PubMed Web of Science ®Google Scholar
• Magalingam KB, Radhakrishnan A, Ping NS, Haleagrahara N. Current concepts of neurodegenerative mechanisms in Alzheimer’s disease. Biomed Res Int. 2018;2018:3740461. doi:10.1155/2018/3740461
   PubMed Web of Science ®Google Scholar
• Paroni G, Bisceglia P, Seripa D. Understanding the amyloid hypothesis in Alzheimer’s disease. J Alzheimers Dis. 2019;68(2):493–510. doi:10.3233/JAD-180802
   PubMed Web of Science ®Google Scholar
• Tiwari MK, Kepp KP. beta-amyloid pathogenesis: chemical properties versus cellular levels. Alzheimers Dement. 2016;12(2):184–194. doi:10.1016/j.jalz.2015.06.1895
   PubMed Web of Science ®Google Scholar
• Roberts KF, Elbert DL, Kasten TP, et al. Amyloid-beta efflux from the central nervous system into the plasma. Ann Neurol. 2014;76(6):837–844. doi:10.1002/ana.24270
   PubMed Web of Science ®Google Scholar
• Deane R, Du Yan S, Submamaryan RK, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med. 2003;9(7):907–913. doi:10.1038/nm890
   PubMed Web of Science ®Google Scholar
• Giedraitis V, Sundelof J, Irizarry MC, et al. The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer’s disease. Neurosci Lett. 2007;427(3):127–131. doi:10.1016/j.neulet.2007.09.023
   PubMed Web of Science ®Google Scholar
• Ovod V, Ramsey KN, Mawuenyega KG, et al. Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017;13(8):841–849. doi:10.1016/j.jalz.2017.06.2266
   PubMed Web of Science ®Google Scholar
• Nakamura A, Kaneko N, Villemagne VL, et al. High performance plasma amyloid-beta biomarkers for Alzheimer’s disease. Nature. 2018;554(7691):249–254. doi:10.1038/nature25456
   PubMed Web of Science ®Google Scholar
• Schindler SE, Bollinger JG, Ovod V, et al. High-precision plasma beta-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019;93(17):e1647–e1659. doi:10.1212/WNL.0000000000008081
   PubMed Web of Science ®Google Scholar
• Vergallo A, Megret L, Lista S, et al. Plasma amyloid beta 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer’s disease. Alzheimers Dement. 2019;15(6):764–775. doi:10.1016/j.jalz.2019.03.009
   PubMed Web of Science ®Google Scholar
• Perez-Grijalba V, Romero J, Pesini P, et al. Plasma Abeta42/40 ratio detects early stages of Alzheimer’s disease and correlates with CSF and neuroimaging biomarkers in the AB255 Study. J Prev Alzheimers Dis. 2019;6(1):34–41. doi:10.14283/jpad.2018.41
   PubMed Web of Science ®Google Scholar
• Wang J, Qiao F, Shang S, et al. Elevation of plasma amyloid-beta level is more significant in early stage of cognitive impairment: a Population-Based Cross-Sectional Study. J Alzheimers Dis. 2018;64(1):61–69. doi:10.3233/JAD-180140
   PubMed Web of Science ®Google Scholar
• van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol. 2006;5(8):655–660. doi:10.1016/S1474-4422(06)70501-4
   PubMed Web of Science ®Google Scholar
• Chouraki V, Beiser A, Younkin L, et al. Plasma amyloid-beta and risk of Alzheimer’s disease in the Framingham Heart Study. Alzheimers Dement. 2015;11(3):249–257 e241. doi:10.1016/j.jalz.2014.07.001
   PubMed Web of Science ®Google Scholar
• Yuan J, Zhang Z, Wen H, et al. Incidence of dementia and subtypes: a cohort study in four regions in China. Alzheimers Dement. 2016;12(3):262–271. doi:10.1016/j.jalz.2015.02.011
   PubMed Web of Science ®Google Scholar
• Katzman R, Zhang MY, Ouang Ya Q, et al. A Chinese version of the Mini-Mental State Examination; impact of illiteracy in a Shanghai dementia survey. J Clin Epidemiol. 1988;41(10):971–978. doi:10.1016/0895-4356(88)90034-0
   PubMed Web of Science ®Google Scholar
• Bohm M, Schumacher H, Leong D, et al. Systolic blood pressure variation and mean heart rate is associated with cognitive dysfunction in patients with high cardiovascular risk. Hypertension. 2015;65(3):651–661. doi:10.1161/HYPERTENSION-AHA114.04568
   PubMed Web of Science ®Google Scholar
• Shulman KI. Clock-drawing: is it the ideal cognitive screening test? Int J Geriatr Psychiatry. 2000;15(6):548–561. doi:10.1002/1099-1166(200006)15:6<548::aid-gps242>3.0.co;2-u
   PubMed Web of Science ®Google Scholar
• Fuld PA, Masur DM, Blau AD, Crystal H, Aronson MK. Object-memory evaluation for prospective detection of dementia in normal functioning elderly: predictive and normative data. J Clin Exp Neuropsychol. 1990;12(4):520–528. doi:10.1080/01688639008400998
   PubMed Web of Science ®Google Scholar
• Henry JD, Crawford JR, Phillips LH. Verbal fluency performance in dementia of the Alzheimer’s type: a meta-analysis. Neuropsychologia. 2004;42(9):112–1222. doi:10.1016/j.neuropsychologia.2004.02.001
   Web of Science ®Google Scholar
• Johanson AM, Gustafson L, Risberg J. Behavioral observations during performance of the WAIS Block Design Test related to abnormalities of regional cerebral blood flow in organic dementia. J Clin Exp Neuropsychol. 1986;8(3):201–209. doi:10.1080/01688638608401312
   PubMed Web of Science ®Google Scholar
• Simard M, van Reekum R. Memory assessment in studies of cognition- enhancing drugs for Alzheimer’s disease. Drugs Aging. 1999;14(3):197–230. doi:10.2165/00002512-199914030-00004
   PubMed Web of Science ®Google Scholar
• First MB. Diagnostic and statistical manual of mental disorders, 5th edition, and clinical utility. J Nerv Ment Dis. 2013;201(9):727–729. doi:10.1097/NMD.0b013e3182a2168a
   PubMed Web of Science ®Google Scholar
• McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer’s disease. Neurology. 1984;34(7):939–944. doi:10.1212/wnl.347.939
   PubMed Web of Science ®Google Scholar
• Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43(2):250–260. doi:10.1212/wnl.43.2.250
   PubMed Web of Science ®Google Scholar
• Vega JN, Newhouse PA. Mild cognitive impairment: diagnosis, longitudinal course, and emerging treatments. Curr Psychiatry Rep. 2014;16(10):490. doi:10.1007/s11920-014-0490-8
   PubMed Web of Science ®Google Scholar
• Hensel A, Angermeyer MC, Riedel-Heller SG. Measuring cognitive change in older adults: reliable change indices for the Mini-Mental State Examination. J Neurol Neurosurg Psychiatry. 2007;78(12):1298–1303. doi:10.1136/jnnp.2006.109074
   PubMed Web of Science ®Google Scholar
• Anderson C, Teo K, Gao P, et al. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol. 2011;10(1):43–53. doi:10.1016/S1474-4422(10)70250-7
   PubMed Web of Science ®Google Scholar
• Lay-Flurrie SL, Sheppard JP, Stevens RJ, et al. Impact of changes to national hypertension guidelines on hypertension management and outcomes in the United Kingdom. Hypertension. 2020;75(2):356–364. doi:10.1161/HYPERTENSIONAHA.119.13926
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet. 2017;389(10085):2239–2251. doi:10.1016/S0140-6736(17)30058-2
   PubMed Web of Science ®Google Scholar
• Olsson B, Lautner R, Andreasson U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673–684. doi:10.1016/S1474-4422(16)00070-3
   PubMed Web of Science ®Google Scholar
• Schupf N, Tang MX, Fukuyama H, et al. Peripheral Abeta subspecies as risk biomarkers of Alzheimer’s disease. Proc Natl Acad Sci USA. 2008;105(37):14052–14057. doi:10.1073/pnas.0805902105
   PubMed Web of Science ®Google Scholar
• Hilal S, Wolters FJ, Verbeek MM, et al. Plasma amyloid-beta levels, cerebral atrophy and risk of dementia: a population-based study. Alzheimers Res Ther. 2018;10(1):63. doi:10.1186/s13195-018-0395-6
   PubMed Web of Science ®Google Scholar
• de Wolf F, Ghanbari M, Licher S, et al. Plasma tau, neurofilament light chain and amyloid-beta levels and risk of dementia; a population-based cohort study. Brain. 2020;143(4):1220–1232. doi:10.1093/brain/awaa054
   PubMed Web of Science ®Google Scholar
• Iulita MF, Ganesh A, Pentz R, et al. Identification and preliminary validation of a plasma profile associated with cognitive decline in Dementia and at-risk individuals: a retrospective cohort analysis. J Alzheimers Dis. 2019;67(1):327–341. doi:10.3233/JAD-180970
   PubMed Web of Science ®Google Scholar
• Giudici KV, de Souto Barreto P, Guyonnet S, et al. Assessment of plasma Amyloid-β 42/40 and cognitive decline among community-dwelling older adults. JAMA Netw Open. 2020;3(12):e2028634. doi:10.1001/jamanetworkopen.2020.28634
   PubMed Web of Science ®Google Scholar
• Shahpasand-Kroner H, Klafki HW, Bauer C, et al. A two-step immunoassay for the simultaneous assessment of Abeta38, Abeta40 and Abeta42 in human blood plasma supports the Abeta42/Abeta40 ratio as a promising biomarker candidate of Alzheimer’s disease. Alzheimers Res Ther. 2018;10(1):121. doi:10.1186/s13195-018-0448-x
   PubMed Web of Science ®Google Scholar
• Verberk IMW, Hendriksen HMA, van Harten AC, et al. Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project. Neurobiol Aging. 2020;89:99–107. doi:10.1016/j.neurobiolaging.2020.01.007
   PubMed Web of Science ®Google Scholar
• Verberk IMW, Slot RE, Verfaillie SCJ, et al. Plasma amyloid as prescreener for the earliest Alzheimer pathological changes. Ann Neurol. 2018;84(5):648–658. doi:10.1002/ana.25334
   PubMed Web of Science ®Google Scholar
• Cullen NC, Leuzy A, Janelidze S, et al. Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. Nat Commun. 2021;12(1):3555. doi:10.1038/s41467-021-23746-0
   PubMed Web of Science ®Google Scholar
• Gao F, Shang S, Chen C, et al. Non-linear relationship between plasma amyloid-β 40 level and cognitive decline in a cognitively normal population. Front Aging Neurosci. 2020;12:557005. doi:10.3389/fnagi.2020.557005
   PubMed Web of Science ®Google Scholar
• Lopez OL, Kuller LH, Mehta PD, et al. Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology. 2008;70(19):1664–1671. doi:10.1212/01.wnl.0000306696.82017.66
   PubMed Web of Science ®Google Scholar
• Locascio JJ, Fukumoto H, Yap L, et al. Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease. Arch Neurol. 2008;65(6):776–785. doi:10.1001/archneur.65.6.776
   PubMedGoogle Scholar
• Sagare A, Deane R, Bell RD, et al. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med. 2007;13(9):1029–1031. doi:10.1038/nm1635
   PubMed Web of Science ®Google Scholar
• Younkin SG. Evidence that A beta 42 is the real culprit in Alzheimer’s disease. Ann Neurol. 1995;37(3):287–288. doi:10.1002/ana.410370303
   PubMed Web of Science ®Google Scholar